PT - JOURNAL ARTICLE AU - Mouratidis, Ioannis AU - Chantzi, Nikol AU - Khan, Umair AU - Konnaris, Maxwell A. AU - Chan, Candace S.Y AU - Mareboina, Manvita AU - Georgakopoulos-Soares, Ilias TI - Frequentmers - a novel way to look at metagenomic Next Generation Sequencing data and an application in detecting liver cirrhosis AID - 10.1101/2023.09.19.23295771 DP - 2023 Jan 01 TA - medRxiv PG - 2023.09.19.23295771 4099 - http://medrxiv.org/content/early/2023/09/19/2023.09.19.23295771.short 4100 - http://medrxiv.org/content/early/2023/09/19/2023.09.19.23295771.full AB - Early detection of human disease is associated with improved clinical outcomes. However, many diseases are often detected at an advanced, symptomatic stage where patients are past efficacious treatment periods and can result in less favorable outcomes. Therefore, methods that can accurately detect human disease at a presymptomatic stage are urgently needed. Here, we introduce “frequentmers”; short sequences that are specific and recurrently observed in either patient or healthy control samples, but not in both. We showcase the utility of frequentmers for the detection of liver cirrhosis using metagenomic Next Generation Sequencing data from stool samples of patients and controls. We develop classification models for the detection of liver cirrhosis and achieve an AUC score of 0.91 using ten-fold cross-validation. A small subset of 200 frequentmers can achieve comparable results in detecting liver cirrhosis. Finally, we identify the microbial organisms in liver cirrhosis samples, which are associated with the most predictive frequentmer biomarkers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementI.M., N.C., M.K., and I.G.S. were funded by the startup funds from the Penn State College of Medicine. We would like to thank Martin Hemberg for offering useful comments. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe analyzed during the current study are available in the European Nucleotide Archive repository, PRJEB6337.